A federal jury in Fort Lauderdale convicted two Maryland brothers who owned a pharmaceutical wholesale company on October 29, 2025, for their roles in a scheme to purchase and resell more than $92 million worth of illegally obtained misbranded HIV drugs.
According to court documents and evidence presented at trial, the brothers, of Easton, Maryland, owned and operated the pharmaceutical wholesale company. Their co-owner and co-defendant previously pleaded guilty to conspiring to commit wire fraud with them.
Trial evidence showed that the brothers conspired with at least five black-market suppliers to purchase HIV medications obtained through patient “buyback schemes,” in which patients sold their prescribed medications. They then resold the drugs to thousands of pharmacies nationwide, using falsified paperwork to make the medications appear to have come from legitimate distributors.
Supplier 1 testified that he purchased HIV drugs from patients on the street, removed the original prescription labels, and packaged the bottles in cardboard boxes—sometimes scavenged from trash on pick-up days—before shipping them to the brothers. On one occasion, he used a diaper box he found on the street because it was sturdy enough to hold the bottles. In a separate shipment, he sent approximately $500,000 worth of HIV medications in a single cardboard box. Many of the bottles were dirty, scuffed, and missing patient instructions, yet the brothers accepted and resold them with falsified paperwork concealing their origin.
In total, the brothers purchased and resold more than $35 million in black-market HIV drugs from Supplier 1 and more than $42 million from Supplier 2, whose leaders were based in Miami. One of those leaders has already been convicted and sentenced to 15 years in prison. Together, these purchases accounted for a substantial portion of the more than $92 million in illegally obtained medications sold by the company.
Throughout the conspiracy, pharmacies repeatedly complained that the drugs purchased from the wholesale company were dirty, tampered with, or contained the wrong medication. On at least a dozen occasions, pharmacies reported receiving bottles labeled as HIV medication that instead contained other drugs, including Seroquel, an anti-psychotic, and pain medication.
One patient who ingested Seroquel believing it was his prescribed HIV medication lost consciousness for 24 hours. Evidence at trial established that missing even a single dose of HIV medication can increase a patient’s viral load and heighten the risk of HIV transmission, particularly in areas with high infection rates.
A former attorney for the brothers testified that they concealed and misrepresented material information while seeking legal advice about pharmacy complaints and reporting obligations to the Food and Drug Administration (FDA). According to the evidence, the brothers failed to report numerous incidents to the FDA involving pharmacies that had received incorrect or tampered medications.
The wholesale company’s former director of compliance testified over four days that she repeatedly warned the brothers about the risks of purchasing from black-market suppliers, but her concerns were ignored. She testified that one of the brothers falsely told her the company could continue doing business with Supplier 1 because the lawyers had approved it, contradicting both attorney testimony and contemporaneous emails.
After a multi-week trial, the jury convicted each brother of one count of conspiracy to introduce misbranded drugs, two counts of introducing misbranded drugs into interstate commerce, one count of conspiracy to traffic in medical products with false documentation, one count of conspiracy to commit wire fraud, and one count of wire fraud.
Compliance Perspective
Issue
US consumers rely on FDA oversight to ensure that the drugs they receive are safe and effective. Title II of the Drug Supply Chain Security Act (DSCSA) outlines steps to achieve interoperable, electronic tracing of products at the package level to identify and trace certain prescription drugs as they are distributed in the United States. This enhances the FDA’s ability to help protect consumers from exposure to drugs that may be counterfeit, stolen, contaminated, or otherwise harmful. Medications obtained from unlicensed sources may present safety issues since they have been manufactured or held outside of the jurisdiction of the FDA’s oversight. These medications may not be safe and effective for their intended uses and must be avoided in healthcare settings, where medications may only be obtained from authorized sources.
Discussion Points
- Review your medication management policies to ensure they clearly define the requirements for purchasing medications from licensed and authorized sources. Policies should include steps for reporting concerns, documenting compliance, and preventing unauthorized procurement. Consider collaborating with an external consultant to evaluate your policies and suggest enhancements, ensuring they align with current regulatory requirements and best practices.
- Train appropriate staff on F755 Pharmacy Services requirements, including the obligation to obtain medications only from US-licensed pharmacies that dispense FDA-approved products, and their responsibility to ensure this standard is followed during medication administration. Provide education to residents and their representatives at admission and through Resident Council on the facility’s approved pharmacies and the safety reasons medications from unauthorized sources may not be brought into the facility. Med-Net Academy offers the course Medication Administration for Nurses, which reviews the nine rights of medication administration, the nurse’s responsibility to verify correct medications and doses, when to clarify concerns with prescribing and dispensing professionals, and common areas where medication errors occur.
- Regularly audit medication inventories, procurement records, and administration logs to ensure adherence to policies and regulatory standards. If discrepancies or risks are identified, promptly take corrective action. Working with a consultant can provide an objective review and help design audits or mock assessments that highlight potential vulnerabilities before they lead to compliance issues.
*This news alert has been prepared by Med-Net Concepts, Inc. for informational purposes only and is not intended to provide legal advice.*